Hyperglycemia Augments Endothelin-1-Induced Constriction of Human Retinal Venules.
endothelin-1
microvascular complications
retina
vasoconstriction
veins
Journal
Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
22
03
2020
accepted:
17
06
2020
entrez:
4
9
2020
pubmed:
4
9
2020
medline:
4
9
2020
Statut:
epublish
Résumé
Endothelin-1 (ET-1) is a potent vasoactive factor implicated in development of diabetic retinopathy, which is commonly associated with retinal edema and hyperglycemia. Although the vasomotor activity of venules contributes to the regulation of tissue fluid homeostasis, responses of human retinal venules to ET-1 under euglycemia and hyperglycemia remain unknown and the ET-1 receptor subtype corresponding to vasomotor function has not been determined. Herein, we addressed these issues by examining the reactivity of isolated human retinal venules to ET-1, and results from porcine retinal venules were compared. Retinal tissues were obtained from patients undergoing enucleation. Human and porcine retinal venules were isolated and pressurized to assess diameter changes in response to ET-1 after exposure to 5 mM control glucose or 25 mM high glucose for 2 hours. Both human and porcine retinal venules exposed to control glucose developed similar basal tone and constricted comparably to ET-1 in a concentration-dependent manner. ET-1-induced constrictions of human and porcine retinal venules were abolished by ET ET-1 elicits comparable constriction of human and porcine retinal venules by activation of ET Similarities in vasoconstriction to ET-1 between human and porcine retinal venules support the latter as an effective model of the human retinal microcirculation to help identify vascular targets for the treatment of retinal complications in patients with diabetes.
Identifiants
pubmed: 32879758
doi: 10.1167/tvst.9.9.1
pii: TVST-20-2435
pmc: PMC7442874
doi:
Substances chimiques
Endothelin-1
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1Subventions
Organisme : NEI NIH HHS
ID : R01 EY023335
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY024624
Pays : United States
Informations de copyright
Copyright 2020 The Authors.
Déclaration de conflit d'intérêts
Disclosure: Y.-L. Chen, None; R.H. Rosa Jr., None; L. Kuo, None; T.W. Hein, None
Références
Curr Eye Res. 2002 Jan;24(1):6-11
pubmed: 12187489
Clin Sci (Lond). 2010 Aug 17;119(11):453-63
pubmed: 20712600
J Ocul Pharmacol Ther. 2005 Aug;21(4):288-97
pubmed: 16117692
Invest Ophthalmol Vis Sci. 2006 Feb;47(2):693-9
pubmed: 16431969
Retina. 2018 Dec;38(12):2301-2308
pubmed: 28984743
Cardiovasc Res. 2017 Sep 1;113(11):1329-1337
pubmed: 28575410
Acta Ophthalmol. 2014 May;92(3):232-7
pubmed: 23648207
Adv Pharmacol. 2016;77:143-75
pubmed: 27451097
Invest Ophthalmol Vis Sci. 2012 Dec 03;53(13):7943-9
pubmed: 23139282
Med Res Rev. 1992 Jul;12(4):391-421
pubmed: 1528080
Am J Physiol. 1997 Jul;273(1 Pt 2):H104-12
pubmed: 9249480
Retina. 2001;21(6):647-51
pubmed: 11756889
Exp Ther Med. 2019 Jan;17(1):453-458
pubmed: 30651821
Diabetologia. 1994 Jan;37(1):36-42
pubmed: 8150228
Diabetes Res Clin Pract. 1990 Nov-Dec;10(3):257-63
pubmed: 2073873
Exp Eye Res. 2003 May;76(5):633-40
pubmed: 12697427
Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3329-36
pubmed: 19151386
Exp Eye Res. 2018 Dec;177:181-190
pubmed: 30120928
Invest Ophthalmol Vis Sci. 2005 Jun;46(6):2113-9
pubmed: 15914631
Invest Ophthalmol Vis Sci. 2019 Sep 3;60(12):3762-3767
pubmed: 31499531
Retina. 2012 Feb;32(2):322-9
pubmed: 21886023
J Cardiovasc Pharmacol. 1992;20 Suppl 12:S11-4
pubmed: 1282942
Invest Ophthalmol Vis Sci. 2013 Dec 13;54(14):ORSF81-7
pubmed: 24335073
J Mol Cell Cardiol. 2015 Sep;86:75-84
pubmed: 26211713
Data Brief. 2018 Oct 27;21:1019-1025
pubmed: 30450393
Cytokine. 2010 Mar;49(3):269-74
pubmed: 20015663
Invest Ophthalmol Vis Sci. 2018 Oct 1;59(12):5167-5175
pubmed: 30372743
Dev Ophthalmol. 2017;58:102-138
pubmed: 28351052
Invest Ophthalmol Vis Sci. 2010 Mar;51(3):1583-90
pubmed: 19850828
Diabetes. 2019 Aug;68(8):1624-1634
pubmed: 31088854
Eur J Ophthalmol. 2016 Jun 10;26(4):342-6
pubmed: 26541106
Invest Ophthalmol Vis Sci. 2013 Nov 15;54(12):7587-94
pubmed: 24243985
Proc Natl Acad Sci U S A. 1994 May 24;91(11):4892-6
pubmed: 8197152
Am J Hypertens. 2002 Nov;15(11):967-72
pubmed: 12441216
Mol Vis. 2005 Jul 07;11:461-71
pubmed: 16030497
Invest Ophthalmol Vis Sci. 2014 Apr 07;55(4):2157-65
pubmed: 24609622
Invest Ophthalmol Vis Sci. 2016 Feb;57(2):412-9
pubmed: 26848880
J Pharmacol Sci. 2013;123(2):85-101
pubmed: 24077109
J Ophthalmol. 2010;2010:354645
pubmed: 21461356
Invest Ophthalmol Vis Sci. 1996 Apr;37(5):886-97
pubmed: 8603873
Nat Rev Dis Primers. 2016 Mar 17;2:16012
pubmed: 27159554
Pharmacol Ther. 2006 Aug;111(2):508-31
pubmed: 16457892
Eye (Lond). 2017 Oct;31(10):1443-1450
pubmed: 28548649
Am J Ophthalmol. 2007 Jun;143(6):1024-6
pubmed: 17524767
Br J Ophthalmol. 1998 May;82(5):498-503
pubmed: 9713055
Invest Ophthalmol Vis Sci. 2016 Aug 1;57(10):4333-40
pubmed: 27556216